---
schema_version: "secwatch.filing_event.v1"
accession: "0001551152-25-000006"
form_type: "8-K"
ticker: "ABBV"
cik: "0001551152"
company_name: "AbbVie Inc."
filed_at: "2025-01-10T23:59:59+00:00"
generated_at: "2026-05-28T04:57:35.958836+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# AbbVie to record $3.5B impairment on emraclidine after Phase 2 schizophrenia failure

## Summary
- Non-cash after-tax impairment charge of ~$3.5B on emraclidine intangible asset from Cerevel acquisition.
- Two Phase 2 EMPOWER trials failed to meet primary endpoint: no significant reduction in PANSS total score vs placebo at week 6.
- Remaining Cerevel-related intangible assets of ~$3.6B continue to be evaluated for potential impairment.
- Impairment reflects significant decrease in estimated future cash flows for emraclidine.

## SEC filing metadata
- accession: 0001551152-25-000006
- form_type: 8-K
- ticker: ABBV
- cik: 0001551152
- company_name: AbbVie Inc.
- filed_at: 2025-01-10T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.06
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000006/0001551152-25-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000006/abbv-20250109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001551152-25-000006
- JSON: https://secwatch.observer/filing/0001551152-25-000006.json
- Plain text: https://secwatch.observer/filing/0001551152-25-000006.txt

## Key facts
- Restructurings & Charges
  AbbVie Inc. announced a impairment with charges of approximately $3.5 billion affecting emraclidine intangible asset acquired as part of the acquisition of Cerevel Therapeutics Holdings, Inc..
  - Type: impairment
  - Charge: approximately $3.5 billion
  - Affected area: emraclidine intangible asset acquired as part of the acquisition of Cerevel Therapeutics Holdings, Inc.
  source text: the estimated future cash flows for the product. Based on the revised cash flows, the company estimates a non-cash after-tax intangible asset impairment charge of approximately $3.5 billion. AbbVie continues to evaluate information with respect to the Cerevel-related clinical development programs and will monitor the remaining intangible assets of approximately $3.6
  evidence_url: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000006/0001551152-25-000006-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.